Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report)’s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.00 and traded as high as $9.00. Hemispherx BioPharma shares last traded at $6.70, with a volume of 7,639 shares changing hands.
Hemispherx BioPharma Stock Performance
The stock’s fifty day simple moving average is $0.95.
Hemispherx BioPharma Company Profile
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Featured Stories
- Five stocks we like better than Hemispherx BioPharma
- How to Most Effectively Use the MarketBeat Earnings Screener
- New All-Time Highs Coming for Broadcom? Wall Street Says Yes
- How to Read Stock Charts for Beginners
- Overheated Market? Analysts Watch These Red Flags
- Using the MarketBeat Dividend Tax Calculator
- 3 Reasons AMD Could Be the Hottest Stock of the Summer
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
